Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance
Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens...
Gespeichert in:
Veröffentlicht in: | Seminars in immunology 2017-04, Vol.30, p.67-80 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 80 |
---|---|
container_issue | |
container_start_page | 67 |
container_title | Seminars in immunology |
container_volume | 30 |
creator | Campana, Raffaela Huang, Huey-Jy Freidl, Raphaela Linhart, Birgit Vrtala, Susanne Wekerle, Thomas Karaulov, Alexander Valenta, Rudolf |
description | Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing allergens or allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined allergen molecules and/or allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined recombinant allergens/allergen derivatives and allergen-derived synthetic peptides from the most common allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy. |
doi_str_mv | 10.1016/j.smim.2017.08.017 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1942701415</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1044532317300696</els_id><sourcerecordid>1942701415</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-582e6655b027aba655d6dad7d6deb91bc077aaa9d190faf390d287debf3d9a93</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVJaT7aP9BD0LEXOyPLX4JeypI0gYVAyKkXMZbGrRbbciTvwv77yuy2x1zmHZhnXmZexr4KyAWI-m6Xx9GNeQGiyaHNk3xgVwJUnclatBdrX5ZZJQt5ya5j3AGALFvxiV0WrZJKtuqK_Xoh48fOTTgtHIeBwm-aOE6WzzQvzlLWYSTLcZ6DR_OHIu99OJNHPgc60LQ4P_HuyH3AgS8-jXAy9Jl97HGI9OWsN-z14f5185htn38-bX5sM1MCLFnVFlTXVdVB0WCHqbO1RdukSp0SnYGmQURlhYIee6nAFm2TZr20CpW8Yd9OtunAtz3FRY8uGhoGnMjvoxaqLBoQpagSWpxQE3yMgXo9BzdiOGoBeo1U7_QaqV4j1dDqJGnp9uy_70ay_1f-ZZiA7yeA0pMHR0FH4ygFYF0gs2jr3Xv-fwHfq4ny</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1942701415</pqid></control><display><type>article</type><title>Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Campana, Raffaela ; Huang, Huey-Jy ; Freidl, Raphaela ; Linhart, Birgit ; Vrtala, Susanne ; Wekerle, Thomas ; Karaulov, Alexander ; Valenta, Rudolf</creator><creatorcontrib>Campana, Raffaela ; Huang, Huey-Jy ; Freidl, Raphaela ; Linhart, Birgit ; Vrtala, Susanne ; Wekerle, Thomas ; Karaulov, Alexander ; Valenta, Rudolf</creatorcontrib><description>Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing allergens or allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined allergen molecules and/or allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined recombinant allergens/allergen derivatives and allergen-derived synthetic peptides from the most common allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy.</description><identifier>ISSN: 1044-5323</identifier><identifier>EISSN: 1096-3618</identifier><identifier>DOI: 10.1016/j.smim.2017.08.017</identifier><identifier>PMID: 28939389</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Administration, Oral ; Allergen ; Allergen-specific immunotherapy ; Allergens - genetics ; Allergens - immunology ; Allergens - therapeutic use ; Allergy ; Allergy prevention ; Animals ; Humans ; Hypersensitivity - immunology ; Hypersensitivity - therapy ; Immune Tolerance ; Immunodominant Epitopes - genetics ; Immunoglobulin E - metabolism ; Oral tolerance induction ; Peptides - genetics ; Peptides - therapeutic use ; Recombinant allergen ; Recombinant Proteins - genetics ; Recombinant Proteins - therapeutic use ; T cell peptides</subject><ispartof>Seminars in immunology, 2017-04, Vol.30, p.67-80</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-582e6655b027aba655d6dad7d6deb91bc077aaa9d190faf390d287debf3d9a93</citedby><cites>FETCH-LOGICAL-c400t-582e6655b027aba655d6dad7d6deb91bc077aaa9d190faf390d287debf3d9a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.smim.2017.08.017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28939389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Campana, Raffaela</creatorcontrib><creatorcontrib>Huang, Huey-Jy</creatorcontrib><creatorcontrib>Freidl, Raphaela</creatorcontrib><creatorcontrib>Linhart, Birgit</creatorcontrib><creatorcontrib>Vrtala, Susanne</creatorcontrib><creatorcontrib>Wekerle, Thomas</creatorcontrib><creatorcontrib>Karaulov, Alexander</creatorcontrib><creatorcontrib>Valenta, Rudolf</creatorcontrib><title>Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance</title><title>Seminars in immunology</title><addtitle>Semin Immunol</addtitle><description>Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing allergens or allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined allergen molecules and/or allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined recombinant allergens/allergen derivatives and allergen-derived synthetic peptides from the most common allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy.</description><subject>Administration, Oral</subject><subject>Allergen</subject><subject>Allergen-specific immunotherapy</subject><subject>Allergens - genetics</subject><subject>Allergens - immunology</subject><subject>Allergens - therapeutic use</subject><subject>Allergy</subject><subject>Allergy prevention</subject><subject>Animals</subject><subject>Humans</subject><subject>Hypersensitivity - immunology</subject><subject>Hypersensitivity - therapy</subject><subject>Immune Tolerance</subject><subject>Immunodominant Epitopes - genetics</subject><subject>Immunoglobulin E - metabolism</subject><subject>Oral tolerance induction</subject><subject>Peptides - genetics</subject><subject>Peptides - therapeutic use</subject><subject>Recombinant allergen</subject><subject>Recombinant Proteins - genetics</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>T cell peptides</subject><issn>1044-5323</issn><issn>1096-3618</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVJaT7aP9BD0LEXOyPLX4JeypI0gYVAyKkXMZbGrRbbciTvwv77yuy2x1zmHZhnXmZexr4KyAWI-m6Xx9GNeQGiyaHNk3xgVwJUnclatBdrX5ZZJQt5ya5j3AGALFvxiV0WrZJKtuqK_Xoh48fOTTgtHIeBwm-aOE6WzzQvzlLWYSTLcZ6DR_OHIu99OJNHPgc60LQ4P_HuyH3AgS8-jXAy9Jl97HGI9OWsN-z14f5185htn38-bX5sM1MCLFnVFlTXVdVB0WCHqbO1RdukSp0SnYGmQURlhYIee6nAFm2TZr20CpW8Yd9OtunAtz3FRY8uGhoGnMjvoxaqLBoQpagSWpxQE3yMgXo9BzdiOGoBeo1U7_QaqV4j1dDqJGnp9uy_70ay_1f-ZZiA7yeA0pMHR0FH4ygFYF0gs2jr3Xv-fwHfq4ny</recordid><startdate>201704</startdate><enddate>201704</enddate><creator>Campana, Raffaela</creator><creator>Huang, Huey-Jy</creator><creator>Freidl, Raphaela</creator><creator>Linhart, Birgit</creator><creator>Vrtala, Susanne</creator><creator>Wekerle, Thomas</creator><creator>Karaulov, Alexander</creator><creator>Valenta, Rudolf</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201704</creationdate><title>Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance</title><author>Campana, Raffaela ; Huang, Huey-Jy ; Freidl, Raphaela ; Linhart, Birgit ; Vrtala, Susanne ; Wekerle, Thomas ; Karaulov, Alexander ; Valenta, Rudolf</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-582e6655b027aba655d6dad7d6deb91bc077aaa9d190faf390d287debf3d9a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Oral</topic><topic>Allergen</topic><topic>Allergen-specific immunotherapy</topic><topic>Allergens - genetics</topic><topic>Allergens - immunology</topic><topic>Allergens - therapeutic use</topic><topic>Allergy</topic><topic>Allergy prevention</topic><topic>Animals</topic><topic>Humans</topic><topic>Hypersensitivity - immunology</topic><topic>Hypersensitivity - therapy</topic><topic>Immune Tolerance</topic><topic>Immunodominant Epitopes - genetics</topic><topic>Immunoglobulin E - metabolism</topic><topic>Oral tolerance induction</topic><topic>Peptides - genetics</topic><topic>Peptides - therapeutic use</topic><topic>Recombinant allergen</topic><topic>Recombinant Proteins - genetics</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>T cell peptides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Campana, Raffaela</creatorcontrib><creatorcontrib>Huang, Huey-Jy</creatorcontrib><creatorcontrib>Freidl, Raphaela</creatorcontrib><creatorcontrib>Linhart, Birgit</creatorcontrib><creatorcontrib>Vrtala, Susanne</creatorcontrib><creatorcontrib>Wekerle, Thomas</creatorcontrib><creatorcontrib>Karaulov, Alexander</creatorcontrib><creatorcontrib>Valenta, Rudolf</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Campana, Raffaela</au><au>Huang, Huey-Jy</au><au>Freidl, Raphaela</au><au>Linhart, Birgit</au><au>Vrtala, Susanne</au><au>Wekerle, Thomas</au><au>Karaulov, Alexander</au><au>Valenta, Rudolf</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance</atitle><jtitle>Seminars in immunology</jtitle><addtitle>Semin Immunol</addtitle><date>2017-04</date><risdate>2017</risdate><volume>30</volume><spage>67</spage><epage>80</epage><pages>67-80</pages><issn>1044-5323</issn><eissn>1096-3618</eissn><abstract>Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing allergens or allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined allergen molecules and/or allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined recombinant allergens/allergen derivatives and allergen-derived synthetic peptides from the most common allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28939389</pmid><doi>10.1016/j.smim.2017.08.017</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1044-5323 |
ispartof | Seminars in immunology, 2017-04, Vol.30, p.67-80 |
issn | 1044-5323 1096-3618 |
language | eng |
recordid | cdi_proquest_miscellaneous_1942701415 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Administration, Oral Allergen Allergen-specific immunotherapy Allergens - genetics Allergens - immunology Allergens - therapeutic use Allergy Allergy prevention Animals Humans Hypersensitivity - immunology Hypersensitivity - therapy Immune Tolerance Immunodominant Epitopes - genetics Immunoglobulin E - metabolism Oral tolerance induction Peptides - genetics Peptides - therapeutic use Recombinant allergen Recombinant Proteins - genetics Recombinant Proteins - therapeutic use T cell peptides |
title | Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A18%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20allergen%20and%20peptide-based%20approaches%20for%20allergy%20prevention%20by%20oral%20tolerance&rft.jtitle=Seminars%20in%20immunology&rft.au=Campana,%20Raffaela&rft.date=2017-04&rft.volume=30&rft.spage=67&rft.epage=80&rft.pages=67-80&rft.issn=1044-5323&rft.eissn=1096-3618&rft_id=info:doi/10.1016/j.smim.2017.08.017&rft_dat=%3Cproquest_cross%3E1942701415%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1942701415&rft_id=info:pmid/28939389&rft_els_id=S1044532317300696&rfr_iscdi=true |